Aquestive Therapeutics Inc (AQST) - Total Liabilities
Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has total liabilities worth $175.18 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AQST shareholders equity momentum to track the company's year-over-year net asset growth rate.
Aquestive Therapeutics Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how Aquestive Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Aquestive Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Aquestive Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aquestive Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Petpal Pet Nutrition Technology Co Ltd
SHE:300673
|
China | CN¥987.01 Million |
|
China Catalyst Holding Co. Ltd. A
SHG:688267
|
China | CN¥197.87 Million |
|
Poly Union Chemical Holding Group Co Ltd
SHE:002037
|
China | CN¥13.04 Billion |
|
Huaren Pharmaceutical Co Ltd
SHE:300110
|
China | CN¥1.86 Billion |
|
Mobilicom Limited Warrants
NASDAQ:MOBBW
|
USA | $11.91 Million |
|
Western Copper and Gold Corp
TO:WRN
|
Canada | CA$3.00 Million |
|
Solid Power Inc
NASDAQ:SLDP
|
USA | $29.27 Million |
|
Orange County Bancorp Inc
NASDAQ:OBT
|
USA | $2.38 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Aquestive Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Aquestive Therapeutics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aquestive Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual total liabilities of Aquestive Therapeutics Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $194.09 Million | +20.12% |
| 2024-12-31 | $161.58 Million | -1.42% |
| 2023-12-31 | $163.91 Million | -6.67% |
| 2022-12-31 | $175.62 Million | +21.85% |
| 2021-12-31 | $144.13 Million | +29.40% |
| 2020-12-31 | $111.38 Million | +31.65% |
| 2019-12-31 | $84.60 Million | +10.20% |
| 2018-12-31 | $76.77 Million | +10.29% |
| 2017-12-31 | $69.61 Million | +22.20% |
| 2016-12-31 | $56.97 Million | +2873.12% |
| 2006-12-31 | $1.92 Million | -74.92% |
| 2005-12-31 | $7.64 Million | -- |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more